ASCO 2019 | The DNA damaging revolution

Thomas Helleday

Aberrations within cancer cell genomes can be capitalized for therapeutic benefit. Thomas Helleday, PhD, of the University of Sheffield, Sheffield, UK, discusses this and how ovarian cancer patients may ultimately be impacted. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics